Strategies for the prevention of infection after solid organ transplantation

References

• Rubin RH. The prevention and treatment of infectious disease in the transplant patient: where are we now and where do we need to go? Transpl. Infect. Dis.6(1), 1–2 (2004).
   PubMedGoogle Scholar
• Delmonico FL. Cadaver donor screening for infectious agents in solid organ transplantation. Clin. Infect. Dis.31(3), 781–786 (2000).
   PubMedGoogle Scholar
• Delmonico FL, Snydman DR. Organ donor screening for infectious diseases: review of practice and implications for transplantation. Transplantation65(5), 603–610 (1998).
   PubMed Web of Science ®Google Scholar
• Anonymous. Screening of donor and recipient prior to solid organ transplantation. Am. J. Transpl.4(Suppl. 10), 10–20 (2004).
   PubMedGoogle Scholar
• Schaffner A. Pretransplant evaluation for infections in donors and recipients of solid organs. Clin. Infect. Dis.33(Suppl. 1), S9–S14 (2001).
   Google Scholar
• Strong DM, Nelson K, Pierce M, Stramer SL. Preventing disease transmission by deceased tissue donors by testing blood for viral nucleic acid. Cell Tissue Bank6(4), 255–262 (2005).
   PubMedGoogle Scholar
• Singh N, Paterson DL. Mycobacterium tuberculosis infection in solid-organ transplant recipients: impact and implications for management. Clin. Infect. Dis.27(5), 1266–1277 (1998).
   PubMed Web of Science ®Google Scholar
• Schluger LK, Sheiner PA, Jonas M et al. Isoniazid hepatotoxicity after orthotopic liver transplantation. Mt Sinai J. Med.63(5–6), 364–369 (1996).
   PubMedGoogle Scholar
• Chaparro SV, Montoya JG, Keeffe EB, Rhee JT, Small PM. Risk of tuberculosis in tuberculin skin test-positive liver transplant patients. Clin. Infect. Dis.29(1), 207–208 (1999).
   PubMed Web of Science ®Google Scholar
• Higgins RM, Cahn AP, Porter D et al. Mycobacterial infections after renal transplantation. Q. J. Med.78(286), 145–153 (1991).
   PubMedGoogle Scholar
• Qunibi WY, al-Sibai MB, Taher S et al. Mycobacterial infection after renal transplantation–report of 14 cases and review of the literature. Q. J. Med.77(282), 1039–1060 (1990).
   PubMedGoogle Scholar
• American Thoracic Society. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am. J. Respir. Crit. Care Med.161(4), S221–S247 (2000).
   PubMed Web of Science ®Google Scholar
• Mazurek GH, Jereb J, Lobue P, Iademarco MF, Metchock B, Vernon A. Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR Recomm. Rep.54(RR-15), 49–55 (2005).
   PubMedGoogle Scholar
• Pirofski LA, Casadevall A. Use of licensed vaccines for active immunization of the immunocompromised host. Clin. Microbiol. Rev.11(1), 1–26 (1998).
   PubMed Web of Science ®Google Scholar
• Avery RK, Ljungman P. Prophylactic measures in the solid-organ recipient before transplantation. Clin. Infect. Dis.33(Suppl. 1), S15–S21 (2001).
   Web of Science ®Google Scholar
• Gardner P, Pickering LK, Orenstein WA, Gershon AA, Nichol KL. Guidelines for quality standards for immunization. Clin. Infect. Dis.35(5), 503–511 (2002).
   PubMedGoogle Scholar
• Duchini A, Goss JA, Karpen S, Pockros PJ. Vaccinations for adult solid-organ transplant recipients: current recommendations and protocols. Clin. Microbiol. Rev.16(3), 357–364 (2003).
   PubMed Web of Science ®Google Scholar
• Cohen J, Rees AJ, Williams G. A prospective randomized controlled trial of perioperative antibiotic prophylaxis in renal transplantation. J. Hosp. Infect.11(4), 357–363 (1988).
   PubMedGoogle Scholar
• Kissel SM, Hoy WE, Freeman RB, Byer B, Yarger JM. Renal transplant urinary tract infections: effect of perioperative antibiotics and earlier catheter removal. NY State J. Med.82(11), 1543–1545 (1982).
   PubMedGoogle Scholar
• Villacian JS, Paya CV. Prevention of infections in solid organ transplant recipients. Transpl. Infect. Dis.1(1), 50–64 (1999).
   PubMedGoogle Scholar
• De SA, McDowell A, Archer L et al.Burkholderia cepacia complex genomovars and pulmonary transplantation outcomes in patients with cystic fibrosis. Lancet358(9295), 1780–1781 (2001).
   PubMedGoogle Scholar
• Maurer JR, Frost AE, Estenne M, Higenbottam T, Glanville AR. International guidelines for the selection of lung transplant candidates. The International Society for Heart and Lung Transplantation, the American Thoracic Society, the American Society of Transplant Physicians, the European Respiratory Society. Transplantation66(7), 951–956 (1998).
   PubMedGoogle Scholar
• Desai D, Desai N, Nightingale P, Elliott T, Neuberger J. Carriage of methicillin-resistant Staphylococcus aureus is associated with an increased risk of infection after liver transplantation. Liver Transpl.9(7), 754–759 (2003).
   PubMed Web of Science ®Google Scholar
• McNeil SA, Malani PN, Chenoweth CE et al. Vancomycin-resistant enterococcal colonization and infection in liver transplant candidates and recipients: a prospective surveillance study. Clin. Infect. Dis.42(2), 195–203 (2006).
   PubMed Web of Science ®Google Scholar
• Paterson DL, Rihs JD, Squier C, Gayowski T, Sagnimeni A, Singh N. Lack of efficacy of mupirocin in the prevention of infections with Staphylococcus aureus in liver transplant recipients and candidates. Transplantation75(2), 194–198 (2003).
   PubMed Web of Science ®Google Scholar
• Bratzler DW, Houck PM. Antimicrobial prophylaxis for surgery: an advisory statement from the National Surgical Infection Prevention Project. Clin. Infect. Dis.38(12), 1706–1715 (2004).
   PubMed Web of Science ®Google Scholar
• Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR. Guideline for prevention of surgical site infection, 1999. Hospital Infection Control Practices Advisory Committee. Infect. Control Hosp. Epidemiol.20(4), 250–278 (1999).
   PubMed Web of Science ®Google Scholar
• van der Waaji D. Colonization pattern of the digestive tract by potentially pathogenic microorganisms: colonization-controlling mechanisms and consequences for antibiotic treatment. Infection11(Suppl. 2), S90–S92 (1983).
   Google Scholar
• Patel R, Paya CV. Infections in solid-organ transplant recipients. Clin. Microbiol. Rev.10(1), 86–124 (1997).
   PubMed Web of Science ®Google Scholar
• Alexander BD, Tapson VF. Infectious complications of lung transplantation. Transpl. Infect. Dis.3(3), 128–137 (2001).
   PubMedGoogle Scholar
• Speich R, van der Bij W. Epidemiology and management of infections after lung transplantation. Clin. Infect. Dis.33(Suppl. 1), S58–S65 (2001).
   Google Scholar
• Ruiz I, Gavalda J, Monforte V et al. Donor-to-host transmission of bacterial and fungal infections in lung transplantation. Am. J. Transpl.6(1), 178–182 (2006).
   PubMed Web of Science ®Google Scholar
• Chernish RN, Aaron SD. Approach to resistant Gram-negative bacterial pulmonary infections in patients with cystic fibrosis. Curr. Opin. Pulm. Med.9(6), 509–515 (2003).
   PubMedGoogle Scholar
• Lumbreras C, Lizasoain M, Moreno E et al. Major bacterial infections following liver transplantation: a prospective study. Hepatogastroenterology39(4), 362–365 (1992).
   PubMedGoogle Scholar
• van der Waaji D, Manson WL, Arends JP, de Vries-Hospers HG. Clinical use of selective decontamination: the concept. Intensive Care Med.16(Suppl. 3), S212–S216 (1990).
   PubMedGoogle Scholar
• Gorensek MJ, Carey WD, Washington JA, Vogt DP, Broughan TA, Westveer MK. Selective bowel decontamination with quinolones and nystatin reduces Gram-negative and fungal infections in orthotopic liver transplant recipients. Cleve. Clin. J. Med.60(2), 139–144 (1993).
   PubMedGoogle Scholar
• Hjortrup A, Rasmussen A, Hansen BA et al. Early bacterial and fungal infections in liver transplantation after oral selective bowel decontamination. Transpl. Proc.29(7), 3106–3110 (1997).
   PubMedGoogle Scholar
• Kuo PC, Bartlett ST, Lim JW, Plotkin JS, Wilson S, Johnson LB. Selective bowel decontamination in hospitalized patients awaiting liver transplantation. Am. J. Surg.174(6), 745–748 (1997).
   PubMedGoogle Scholar
• Steffen R, Reinhartz O, Blumhardt G et al. Bacterial and fungal colonization and infections using oral selective bowel decontamination in orthotopic liver transplantations. Transpl. Int.7(2), 101–108 (1994).
   PubMedGoogle Scholar
• Raakow R, Steffen R, Lefebre B, Bechstein WO, Blumhardt G, Neuhaus P. Selective bowel decontamination effectively prevents Gram-negative bacterial infections after liver transplantation. Transpl. Proc.22(4), 1556–1557 (1990).
   PubMed Web of Science ®Google Scholar
• Zwaveling JH, Maring JK, Klompmaker IJ et al. Selective decontamination of the digestive tract to prevent postoperative infection: a randomized placebo-controlled trial in liver transplant patients. Crit. Care Med.30(6), 1204–1209 (2002).
   PubMed Web of Science ®Google Scholar
• Hellinger WC, Yao JD, Alvarez S et al. A randomized, prospective, double-blinded evaluation of selective bowel decontamination in liver transplantation. Transplantation73(12), 1904–1909 (2002).
   PubMed Web of Science ®Google Scholar
• Arnow PM, Carandang GC, Zabner R, Irwin ME. Randomized controlled trial of selective bowel decontamination for prevention of infections following liver transplantation. Clin. Infect. Dis.22(6), 997–1003 (1996).
   PubMed Web of Science ®Google Scholar
• Safdar N, Said A, Lucey MR. The role of selective digestive decontamination for reducing infection in patients undergoing liver transplantation: a systematic review and meta-analysis. Liver Transpl.10(7), 817–827 (2004).
   PubMed Web of Science ®Google Scholar
• Patel R, Badley AD, Larson-Keller J et al. Relevance and risk factors of enterococcal bacteremia following liver transplantation. Transplantation61(8), 1192–1197 (1996).
   PubMedGoogle Scholar
• Patel R, Cockerill FR, Porayko MK, Osmon DR, Ilstrup DM, Keating MR. Lactobacillemia in liver transplant patients. Clin. Infect. Dis.18(2), 207–212 (1994).
   PubMed Web of Science ®Google Scholar
• Rayes N, Seehofer D, Muller AR, Hansen S, Bengmark S, Neuhaus P. Influence of probiotics and fibre on the incidence of bacterial infections following major abdominal surgery – results of a prospective trial. Z. Gastroenterol.40(10), 869–876 (2002).
   PubMed Web of Science ®Google Scholar
• Rayes N, Seehofer D, Hansen S et al. Early enteral supply of lactobacillus and fiber versus selective bowel decontamination: a controlled trial in liver transplant recipients. Transplantation74(1), 123–127 (2002).
   PubMed Web of Science ®Google Scholar
• Rayes N, Seehofer D, Theruvath T et al. Supply of pre- and probiotics reduces bacterial infection rates after liver transplantation – a randomized, double-blind trial. Am. J. Transpl.5(1), 125–130 (2005).
   PubMed Web of Science ®Google Scholar
• Larson AM, Chan GC, Wartelle CF et al. Infection complicating percutaneous liver biopsy in liver transplant recipients. Hepatology26(6), 1406–1409 (1997).
   PubMedGoogle Scholar
• Montoya JG, Giraldo LF, Efron B et al. Infectious complications among 620 consecutive heart transplant patients at Stanford University Medical Center. Clin. Infect. Dis.33(5), 629–640 (2001).
   PubMed Web of Science ®Google Scholar
• Smart FW, Naftel DC, Costanzo MR et al. Risk factors for early, cumulative, and fatal infections after heart transplantation: a multi-institutional study. J. Heart Lung Transplant.15(4), 329–341 (1996).
   PubMedGoogle Scholar
• Holman WL, Murrah CP, Ferguson ER, Bourge RC, McGiffin DC, Kirklin JK. Infections during extended circulatory support: University of Alabama at Birmingham experience 1989 to 1994. Ann. Thoracic Surg.61(1), 366–371 (1996).
   PubMedGoogle Scholar
• Moroney DA, Vaca KJ. Infectious complications associated with ventricular assist devices. Am. J. Crit. Care4(3), 204–209 (1995).
   PubMedGoogle Scholar
• Myers TJ, Khan T, Frazier OH. Infectious complications associated with ventricular assist systems. ASAIO J.46(6), S28–S36 (2000).
   PubMedGoogle Scholar
• Springer WE, Wasler A, Radovancevic B et al. Retrospective analysis of infection in patients undergoing support with left ventricular assist systems. ASAIO J.42(5), M763–M765 (1996).
   Google Scholar
• de Gevignev G, Pop C, Delahaye JP. The risk of infective endocarditis after cardiac surgical and interventional procedures. Eur. Heart J.16(Suppl. B), 7–14 (1995).
   Google Scholar
• Grossi P, De Maria R, Caroli A, Zaina MS, Minoli L. Infections in heart transplant recipients: the experience of the Italian heart transplantation program. Italian Study Group on Infections in Heart Transplantation. J. Heart Lung Transplant.11(5), 847–866 (1992).
   PubMed Web of Science ®Google Scholar
• Dajani AS, Taubert KA, Wilson W et al. Prevention of bacterial endocarditis: recommendations by the American Heart Association. Clin. Infect. Dis.25(6), 1448–1458 (1997).
   PubMed Web of Science ®Google Scholar
• Muller V, Becker G, Delfs M, Albrecht KH, Philipp T, Heemann U. Do urinary tract infections trigger chronic kidney transplant rejection in man? J. Urol.159(6), 1826–1829 (1998).
   PubMed Web of Science ®Google Scholar
• Chuang P, Parikh CR, Langone A. Urinary tract infections after renal transplantation: a retrospective review at two US transplant centers. Clin. Transplant.19(2), 230–235 (2005).
   PubMed Web of Science ®Google Scholar
• Takai K, Aoki A, Suga A et al. Urinary tract infections following renal transplantation. Transplant. Proc.30(7), 3140–3141 (1998).
   PubMedGoogle Scholar
• Takai K, Tollemar J, Wilczek HE, Groth CG. Urinary tract infections following renal transplantation. Clin. Transplant.12(1), 19–23 (1998).
   PubMed Web of Science ®Google Scholar
• Erturk E, Burzon DT, Orloff M, Rabinowitz R. Outcome of patients with vesicoureteral reflux after renal transplantation: the effect of pretransplantation surgery on posttransplant urinary tract infections. Urology51(Suppl. 5A), 27–30 (1998).
   PubMedGoogle Scholar
• Lumbreras C, Fernandez I, Velosa J, Munn S, Sterioff S, Paya CV. Infectious complications following pancreatic transplantation: incidence, microbiological and clinical characteristics, and outcome. Clin. Infect. Dis.20(3), 514–520 (1995).
   PubMed Web of Science ®Google Scholar
• Fox BC, Sollinger HW, Belzer FO, Maki DG. A prospective, randomized, double-blind study of trimethoprim-sulfamethoxazole for prophylaxis of infection in renal transplantation: clinical efficacy, absorption of trimethoprim-sulfamethoxazole, effects on the microflora, and the cost-benefit of prophylaxis. Am. J. Med.89(3), 255–274 (1990).
   PubMed Web of Science ®Google Scholar
• Tolkoff-Rubin NE, Cosimi AB, Russell PS, Rubin RH. A controlled study of trimethoprim-sulfamethoxazole prophylaxis of urinary tract infection in renal transplant recipients. Rev. Infect. Dis.4(2), 614–618 (1982).
   PubMedGoogle Scholar
• Moyses NM, Costa RS, Reis MA et al. Use of ciprofloxacin as a prophylactic agent in urinary tract infections in renal transplant recipients. Clin. Transplant11(5 Pt 1), 446–452 (1997).
   PubMedGoogle Scholar
• Cahill BC, Hibbs JR, Savik K et al. Aspergillus airway colonization and invasive disease after lung transplantation. Chest112(5), 1160–1164 (1997).
   PubMed Web of Science ®Google Scholar
• Nunley DR, Ohori P, Grgurich WF et al. Pulmonary aspergillosis in cystic fibrosis lung transplant recipients. Chest114(5), 1321–1329 (1998).
   PubMed Web of Science ®Google Scholar
• O’Neill JM, Schutze GM, Heulitt MJ, Simpson PM, Taylor BJ. Nosocomial infections during extracorporeal membrane oxygenation. Intensive Care Med.27(8), 1247–1253 (2001).
   PubMed Web of Science ®Google Scholar
• Dummer JS, Lazariashvilli N, Barnes J, Ninan M, Milstone AP. A survey of anti-fungal management in lung transplantation. J. Heart Lung Transplant.23(12), 1376–1381 (2004).
   Google Scholar
• Reichenspurner H, Gamberg P, Nitschke M et al. Significant reduction in the number of fungal infections after lung, heart–lung, and heart transplantation using aerosolized amphotericin B prophylaxis. Transpl. Proc.29(1–2), 627–628 (1997).
   PubMed Web of Science ®Google Scholar
• Palmer SM, Drew RH, Whitehouse JD et al. Safety of aerosolized amphotericin B lipid complex in lung transplant recipients. Transplantation72(3), 545–548 (2001).
   PubMed Web of Science ®Google Scholar
• Shitrit D, Ollech JE, Ollech A et al. Itraconazole prophylaxis in lung transplant recipients receiving tacrolimus (FK 506), efficacy and drug interaction. J. Heart Lung Transplant.24(12), 2148–2152 (2005).
   PubMedGoogle Scholar
• Hamacher J, Spiliopoulos A, Kurt AM, Nicod LP. Pre-emptive therapy with azoles in lung transplant patients. Geneva Lung Transplantation Group. Eur. Respir. J.13(1), 180–186 (1999).
   PubMed Web of Science ®Google Scholar
• Anonymous. Fungal infections. Am. J. Transplant.4(Suppl. 10), 110–134 (2004).
   PubMedGoogle Scholar
• Paya CV. Fungal infections in solid-organ transplantation. Clin. Infect. Dis.16(5), 677–688 (1993).
   PubMed Web of Science ®Google Scholar
• Paya CV. Prevention of fungal and hepatitis virus infections in liver transplantation. Clin. Infect. Dis.33(Suppl. 1), S47–S52 (2001).
   Google Scholar
• Singh N, Avery RK, Munoz P et al. Trends in risk profiles for and mortality associated with invasive aspergillosis among liver transplant recipients. Clin. Infect. Dis.36(1), 46–52 (2003).
   PubMed Web of Science ®Google Scholar
• Lumbreras C, Cuervas-Mons V, Jara P et al. Randomized trial of fluconazole versus nystatin for the prophylaxis of Candida infection following liver transplantation. J. Infect. Dis.174(3), 583–588 (1996).
   PubMedGoogle Scholar
• Winston DJ, Pakrasi A, Busuttil RW. Prophylactic fluconazole in liver transplant recipients. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med.131(10), 729–737 (1999).
   PubMed Web of Science ®Google Scholar
• Playford EG, Webster AC, Sorell TC, Craig JC. Antifungal agents for preventing fungal infections in solid organ transplant recipients. Cochrane Database Syst. Rev. (3), CD004291 (2004).
   Google Scholar
• Tollemar J, Hockerstedt K, Ericzon BG, Jalanko H, Ringden O. Prophylaxis with liposomal amphotericin B (AmBisome) prevents fungal infections in liver transplant recipients: long-term results of a randomized, placebo-controlled trial. Transpl. Proc.27(1), 1195–1198 (1995).
   PubMedGoogle Scholar
• Singh N, Paterson DL, Gayowski T, Wagener MM, Marino IR. Preemptive prophylaxis with a lipid preparation of amphotericin B for invasive fungal infections in liver transplant recipients requiring renal replacement therapy. Transplantation71(7), 910–913 (2001).
   PubMedGoogle Scholar
• Singhal S, Ellis RW, Jones SG et al. Targeted prophylaxis with amphotericin B lipid complex in liver transplantation. Liver Transpl.6(5), 588–595 (2000).
   PubMed Web of Science ®Google Scholar
• Sharpe MD, Ghent C, Grant D, Horbay GL, McDougal J, David CW. Efficacy and safety of itraconazole prophylaxis for fungal infections after orthotopic liver transplantation: a prospective, randomized, double-blind study. Transplantation76(6), 977–983 (2003).
   PubMedGoogle Scholar
• Winston DJ, Busuttil RW. Randomized controlled trial of oral itraconazole solution versus intravenous/oral fluconazole for prevention of fungal infections in liver transplant recipients. Transplantation74(5), 688–695 (2002).
   PubMed Web of Science ®Google Scholar
• Singh N, Paterson DL. Aspergillus infections in transplant recipients. Clin. Microbiol. Rev.18(1), 44–69 (2005).
   PubMed Web of Science ®Google Scholar
• Malani PN, Dyke DB, Pagani FD, Chenoweth CE. Nosocomial infections in left ventricular assist device recipients. Clin. Infect. Dis.34(10), 1295–1300 (2002).
   PubMed Web of Science ®Google Scholar
• Skinner JL, Harris C, Aaron MF et al. Cost-benefit analysis of extended antifungal prophylaxis in ventricular assist devices. ASAIO J.46(5), 587–589 (2000).
   PubMed Web of Science ®Google Scholar
• Benedetti E, Gruessner AC, Troppmann C et al. Intra-abdominal fungal infections after pancreatic transplantation: incidence, treatment, and outcome. J. Am. Coll. Surg.183(4), 307–316 (1996).
   PubMedGoogle Scholar
• Stratta RJ. Ganciclovir/acyclovir and fluconazole prophylaxis after simultaneous kidney-pancreas transplantation. Transpl. Proc.30(2), 262 (1998).
   PubMedGoogle Scholar
• Safdar N, Slattery WR, Knasinski V et al. Predictors and outcomes of candiduria in renal transplant recipients. Clin. Infect. Dis.40(10), 1413–1421 (2005).
   PubMed Web of Science ®Google Scholar
• Fishman JA. Pneumocystis carinii and parasitic infections in transplantation. Infect. Dis. Clin. North Am.9(4), 1005–1044 (1995).
   PubMedGoogle Scholar
• Fishman JA. Treatment of infection due to Pneumocystis carinii. Antimicrob. Agents Chemother.42(6), 1309–1314 (1998).
   PubMed Web of Science ®Google Scholar
• Fishman JA. Prevention of infection due to Pneumocystis carinii. Antimicrob. Agents Chemother.42(5), 995–1004 (1998).
   PubMed Web of Science ®Google Scholar
• Fishman JA. Prevention of infection caused by Pneumocystis carinii in transplant recipients. Clin. Infect. Dis.33(8), 1397–1405 (2001).
   PubMed Web of Science ®Google Scholar
• Falagas ME, Arbo M, Ruthazer R et al. Cytomegalovirus disease is associated with increased cost and hospital length of stay among orthotopic liver transplant recipients. Transplantation63(11), 1595–1601 (1997).
   PubMed Web of Science ®Google Scholar
• Paya CV. Economic impact of cytomegalovirus in solid organ transplantation. Transpl. Infect. Dis.3(Suppl. 2), 14–19 (2001).
   PubMedGoogle Scholar
• Fateh-Moghadam S, Bocksch W, Wessely R, Jager G, Hetzer R, Gawaz M. Cytomegalovirus infection status predicts progression of heart-transplant vasculopathy. Transplantation76(10), 1470–1474 (2003).
   PubMed Web of Science ®Google Scholar
• Paya CV. Indirect effects of CMV in the solid organ transplant patient. Transpl. Infect. Dis.1 (Suppl. 1), 8–12 (1999).
   PubMedGoogle Scholar
• Paya CV. Prevention of cytomegalovirus disease in recipients of solid-organ transplants. Clin. Infect. Dis.32(4), 596–603 (2001).
   PubMed Web of Science ®Google Scholar
• Paya C, Humar A, Dominguez E et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am. J. Transplant.4(4), 611–620 (2004).
   PubMed Web of Science ®Google Scholar
• Jain A, Orloff M, Kashyap R et al. Does valganciclovir hydrochloride (valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients? Transpl. Proc.37(7), 3182–3186 (2005).
   PubMedGoogle Scholar
• Humar A, Kumar D, Preiksaitis J et al. A trial of valganciclovir prophylaxis for cytomegalovirus prevention in lung transplant recipients. Am. J. Transplant.5(6), 1462–1468 (2005).
   PubMed Web of Science ®Google Scholar
• Zamora MR, Nicolls MR, Hodges TN et al. Following universal prophylaxis with intravenous ganciclovir and cytomegalovirus immune globulin, valganciclovir is safe and effective for prevention of CMV infection following lung transplantation. Am. J. Transplant.4(10), 1635–1642 (2004).
   PubMed Web of Science ®Google Scholar
• Boivin G, Goyette N, Gilbert C et al. Absence of cytomegalovirus-resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients. J. Infect. Dis.189(9), 1615–1618 (2004).
   PubMed Web of Science ®Google Scholar
• Boivin G, Goyette N, Gilbert C, Humar A, Covington E. Clinical impact of ganciclovir-resistant cytomegalovirus infections in solid organ transplant patients. Transpl. Infect. Dis.7(3–4), 166–170 (2005).
   PubMed Web of Science ®Google Scholar
• Boivin G, Erice A, Crane DD, Dunn DL, Balfour HH Jr. Ganciclovir susceptibilities of cytomegalovirus (CMV) isolates from solid organ transplant recipients with CMV viremia after antiviral prophylaxis. J. Infect. Dis.168(2), 332–335 (1993).
   PubMedGoogle Scholar
• Paya CV, Wilson JA, Espy MJ et al. Preemptive use of oral ganciclovir to prevent cytomegalovirus infection in liver transplant patients: a randomized, placebo-controlled trial. J. Infect. Dis.185(7), 854–860 (2002).
   Google Scholar
• Singh N. Preemptive therapy versus universal prophylaxis with ganciclovir for cytomegalovirus in solid organ transplant recipients. Clin. Infect. Dis.32(5), 742–751 (2001).
   PubMed Web of Science ®Google Scholar
• Kalil AC, Levitsky J, Lyden E, Stoner J, Freifeld AG. Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann. Intern. Med.143(12), 870–880 (2005).
   PubMed Web of Science ®Google Scholar
• Strippoli GF, Hodson EM, Jones C, Craig JC. Preemptive treatment for cytomegalovirus viremia to prevent cytomegalovirus disease in solid organ transplant recipients. Transplantation81(2), 139–145 (2006).
   PubMed Web of Science ®Google Scholar
• Sia IG, Patel R. New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipients. Clin. Microbiol. Rev.13(1), 83–121 (2000).
   PubMed Web of Science ®Google Scholar
• Preiksaitis JK, Brennan DC, Fishman J, Allen U. Canadian society of transplantation consensus workshop on cytomegalovirus management in solid organ transplantation final report. Am. J. Transplant.5(2), 218–227 (2005).
   PubMed Web of Science ®Google Scholar
• Zamora MR, Davis RD, Leonard C. Management of cytomegalovirus infection in lung transplant recipients: evidence-based recommendations. Transplantation80(2), 157–163 (2005).
   PubMed Web of Science ®Google Scholar
• az-Pedroche C, Lumbreras C, Del VP et al. Efficacy and safety of valgancyclovir as preemptive therapy for the prevention of cytomegalovirus disease in solid organ transplant recipients. Transplant. Proc.37(9), 3766–3767 (2005).
   PubMedGoogle Scholar
• Singh N, Wannstedt C, Keyes L, Gayowski T, Wagener MM, Cacciarelli TV. Efficacy of valganciclovir administered as preemptive therapy for cytomegalovirus disease in liver transplant recipients: impact on viral load and late-onset cytomegalovirus disease. Transplantation79(1), 85–90 (2005).
   PubMed Web of Science ®Google Scholar
• Mattes FM, Hainsworth EG, Hassan-Walker AF et al. Kinetics of cytomegalovirus load decrease in solid-organ transplant recipients after preemptive therapy with valganciclovir. J. Infect. Dis.191(1), 89–92 (2005).
   PubMed Web of Science ®Google Scholar
• Sia IG, Wilson JA, Groettum CM, Espy MJ, Smith TF, Paya CV. Cytomegalovirus (CMV) DNA load predicts relapsing CMV infection after solid organ transplantation. J. Infect. Dis.181(2), 717–720 (2000).
   PubMed Web of Science ®Google Scholar
• Humar A, Kumar D, Boivin G, Caliendo AM. Cytomegalovirus (CMV) virus load kinetics to predict recurrent disease in solid-organ transplant patients with CMV disease. J. Infect. Dis.186(6), 829–833 (2002).
   PubMed Web of Science ®Google Scholar
• Singh N, Dummer JS, Kusne S et al. Infections with cytomegalovirus and other herpes viruses in 121 liver transplant recipients: transmission by donated organ and the effect of OKT3 antibodies. J. Infect. Dis.158(1), 124–131 (1988).
   PubMed Web of Science ®Google Scholar
• Slifkin M, Doron S, Snydman DR. Viral prophylaxis in organ transplant patients. Drugs64(24), 2763–2792 (2004).
   PubMed Web of Science ®Google Scholar
• Lowance D, Neumayer HH, Legendre CM et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N. Engl. J. Med.340(19), 1462–1470 (1999).
   PubMed Web of Science ®Google Scholar
• Anonymous. Epstein-Barr virus and lymphoproliferative disorders after transplantation. Am. J. Transplant.4(Suppl. 10), 59–65 (2004).
   PubMedGoogle Scholar
• Razonable RR, Paya CV. Herpes virus infections in transplant recipients: current challenges in the clinical management of cytomegalovirus and Epstein-Barr virus infections. Herpes10(3), 60–65 (2003).
   PubMedGoogle Scholar
• Funch DP, Walker AM, Schneider G, Ziyadeh NJ, Pescovitz MD. Ganciclovir and acyclovir reduce the risk of post-transplant lymphoproliferative disorder in renal transplant recipients. Am. J. Transplant.5(12), 2894–2900 (2005).
   PubMed Web of Science ®Google Scholar
• Malouf MA, Chhajed PN, Hopkins P, Plit M, Turner J, Glanville AR. Anti-viral prophylaxis reduces the incidence of lymphoproliferative disease in lung transplant recipients. J. Heart Lung Transplant.21(5), 547–554 (2002).
   PubMed Web of Science ®Google Scholar
• Green M, Reyes J, Webber S, Rowe D. The role of antiviral and immunoglobulin therapy in the prevention of Epstein-Barr virus infection and post-transplant lymphoproliferative disease following solid organ transplantation. Transplant. Infect. Dis.3(2), 97–103 (2001).
   PubMedGoogle Scholar
• Darenkov IA, Marcarelli MA, Basadonna GP et al. Reduced incidence of Epstein-Barr virus-associated posttransplant lymphoproliferative disorder using preemptive antiviral therapy. Transplantation64(6), 848–852 (1997).
   PubMed Web of Science ®Google Scholar
• Davis CL, Harrison KL, McVicar JP et al. Antiviral prophylaxis and the Epstein Barr virus-related post-transplant lymphoproliferative disorder. Clin. Transplant9(1), 53–59 (1995).
   PubMed Web of Science ®Google Scholar
• Humar A, Hebert D, Davies HD et al. A randomized trial of ganciclovir versus ganciclovir plus immune globulin for prophylaxis against Epstein-Barr virus related posttransplant lymphoproliferative disorder. Transplantation81(6), 856–861 (2006).
   PubMed Web of Science ®Google Scholar
• Lee TC, Savoldo B, Rooney CM et al. Quantitative EBV viral loads and immunosuppression alterations can decrease PTLD incidence in pediatric liver transplant recipients. Am. J. Transplant.5(9), 2222–2228 (2005).
   PubMed Web of Science ®Google Scholar
• Scheenstra R, Verschuuren EA, de Haan A et al. The value of prospective monitoring of Epstein-Barr virus DNA in blood samples of pediatric liver transplant recipients. Transpl. Infect. Dis.6(1), 15–22 (2004).
   PubMedGoogle Scholar
• Wagner HJ, Cheng YC, Huls MH et al. Prompt versus preemptive intervention for EBV lymphoproliferative disease. Blood103(10), 3979–3981 (2004).
   PubMed Web of Science ®Google Scholar
• Singh N. Human herpesviruses-6, -7 and -8 in organ transplant recipients. Clin. Microbiol. Infect.6(9), 453–459 (2000).
   PubMedGoogle Scholar
• Singh N, Carrigan DR, Gayowski T, Marino IR. Human herpesvirus-6 infection in liver transplant recipients: documentation of pathogenicity. Transplantation64(5), 674–678 (1997).
   PubMed Web of Science ®Google Scholar
• Mendez JC, Dockrell DH, Espy MJ et al. Human β-herpesvirus interactions in solid organ transplant recipients. J. Infect. Dis.183(2), 179–184 (2001).
   PubMed Web of Science ®Google Scholar
• Dockrell DH, Prada J, Jones MF et al. Seroconversion to human herpesvirus 6 following liver transplantation is a marker of cytomegalovirus disease. J. Infect. Dis.176(5), 1135–1140 (1997).
   PubMedGoogle Scholar
• Yoshida M, Yamada M, Tsukazaki T et al. Comparison of antiviral compounds against human herpesvirus 6 and 7. Antiviral Res.40(1–2), 73–84 (1998).
   PubMed Web of Science ®Google Scholar
• Galarraga MC, Gomez E, de Ona M et al. Influence of ganciclovir prophylaxis on cytomegalovirus, human herpesvirus 6, and human herpesvirus 7 viremia in renal transplant recipients. Transpl. Proc.37(5), 2124–2126 (2005).
   PubMedGoogle Scholar
• Wachs ME, Amend WJ, Ascher NL et al. The risk of transmission of hepatitis B from HBsAg-, HBcAb+, HBIgM- organ donors. Transplantation59(2), 230–234 (1995).
   PubMed Web of Science ®Google Scholar
• Dominguez M, Barcena R, Garcia M, Lopez-Sanroman A, Nuno J. Vaccination against hepatitis B virus in cirrhotic patients on liver transplant waiting list. Liver Transplant.6(4), 440–442 (2000).
   PubMed Web of Science ®Google Scholar
• Engler SH, Sauer PW, Golling M et al. Immunogenicity of two accelerated hepatitis B vaccination protocols in liver transplant candidates. Eur. J. Gastroenterol. Hepatol.13(4), 363–367 (2001).
   PubMedGoogle Scholar
• Kallinowski B, Benz C, Buchholz L, Stremmel W. Accelerated schedule of hepatitis B vaccination in liver transplant candidates. Transpl. Proc.30(3), 797–799 (1998).
   PubMedGoogle Scholar
• Chung RT, Feng S, Delmonico FL. Approach to the management of allograft recipients following the detection of hepatitis B virus in the prospective organ donor. Am. J. Transplant.1(2), 185–191 (2001).
   PubMedGoogle Scholar
• Suehiro T, Shimada M, Kishikawa K et al. Prevention of hepatitis B virus infection from hepatitis B core antibody-positive donor graft using hepatitis B immune globulin and lamivudine in living donor liver transplantation. Liver Internat.25(6), 1169–1174 (2005).
   PubMedGoogle Scholar
• Wang ZF, Zhu ZJ, Shen ZY. Advances in prophylaxis and treatment of recurrent hepatitis B after liver transplantation. Hepatobiliary Pancreat. Dis. Int.4(4), 509–514 (2005).
   PubMedGoogle Scholar
• Terrault N, Roche B, Samuel D. Management of the hepatitis B virus in the liver transplantation setting: a European and an American perspective. Liver Transpl.11(7), 716–732 (2005).
   PubMed Web of Science ®Google Scholar
• Mohanty SR, Cotler SJ. Management of hepatitis B in liver transplant patients. J. Clin. Gastroenterol.39(1), 58–63 (2005).
   PubMedGoogle Scholar
• Seehofer D, Rayes N, Neuhaus P. Prophylaxis and treatment of hepatitis B recurrence after liver transplantation in the antiviral era. Exp. Rev. Anti Infect. Ther.1(2), 307–318 (2003).
   PubMedGoogle Scholar
• Roche B, Samuel D. Evolving strategies to prevent HBV recurrence. Liver Transplant.10(10 Suppl. 2), S74–S85 (2004).
   PubMed Web of Science ®Google Scholar
• Schreibman IR, Schiff ER. Prevention and treatment of recurrent hepatitis B after liver transplantation: the current role of nucleoside and nucleotide analogues. Ann. Clin. Microbiol. Antimicrob.5, 8 (2006).
   PubMedGoogle Scholar
• Baden LR, Katz JT, Franck L et al. Successful toxoplasmosis prophylaxis after orthotopic cardiac transplantation with trimethoprim-sulfamethoxazole. Transplantation75(3), 339–343 (2003).
   PubMedGoogle Scholar
• Stone WJ, Schaffner W. Strongyloides infections in transplant recipients. Semin. Respir. Infect.5(1), 58–64 (1990).
   PubMedGoogle Scholar
• Palau LA, Pankey GA. Strongyloides hyperinfection in a renal transplant recipient receiving cyclosporine: possible Strongyloides stercoralis transmission by kidney transplant. Am. J. Trop. Med. Hyg.57(4), 413–415 (1997).
   PubMedGoogle Scholar
• Immunosuppressive drug interactions with anti-infective agents. Am. J. Transplant.4(Suppl. 10), 164–166 (2004).
   PubMedGoogle Scholar
• Strategies for safe living following solid organ transplantation. Am. J. Transplant.4(Suppl. 10), 156–159 (2004).
   PubMedGoogle Scholar